Rubicon Research Limited IPO
Rubicon Research Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹461–₹485 per share to raise ₹619 crore. The issue was subscribed 103.9× overall (QIBs 130.26×, NIIs 97.61×, retail 35.47×). It listed on 16 Oct 2025 at ₹620 and closed its first day at ₹628, a listing gain of +29.5% versus the ₹485 issue price. It now trades around ₹1,610 (+232.1% versus the issue price).
Frequently asked questions
- How many times was the Rubicon Research Limited IPO subscribed?
- The Rubicon Research Limited IPO was subscribed 103.9× overall — 130.26× in the QIB category, 97.61× among non-institutional investors, 35.47× in retail.
- What were the Rubicon Research Limited IPO listing gains?
- Rubicon Research Limited listed on 16 Oct 2025 at ₹620, closing its first day at ₹628 — a listing gain of +29.5% versus the ₹485 issue price.
- What were the retail allotment odds for the Rubicon Research Limited IPO?
- Retail was subscribed 35.47×, so a single-lot application had roughly a 2.8% chance of allotment (about 1 in 35), and allotment was finalised on 14 Oct 2025.
- What was the price band and lot size of the Rubicon Research Limited IPO?
- The price band was ₹461–₹485 per share, with a minimum lot of 30 shares (₹14,550 at the upper band).
- Who were the registrar and lead manager for the Rubicon Research Limited IPO?
- MUFG Intime India Private Limited was the registrar, and Axis Capital was the book-running lead manager.